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Abstract text 
Effective pharmacovigilance increasingly depends on patients playing their part, but 
the ‘dialogue’ is impeded because of patients’ lack of knowledge of drug development 
and safety measures. However, the main barrier is the language we use, which is not 
the language of the man or woman in the street. Even many grass roots health 
professionals struggle to describe what ‘pharmacovigilance’ means – it is 
meaningless to patients. What words would they understand to describe the process?  
Equally we talk about benefit/risk, whereas what we mean is the chance of benefit 
and the risk of harm. Pharmacovigilance should allow the patient and prescriber to 
understand the benefit/harm balance for a medicine and decide if it is right for them – 
but we currently only given them numerical information about the risk of harm (‘affects 
less than 1 in 10 people’) – and nothing about the chance of benefit. This means a 
truly informed decision is not possible. So, how can we best describe numerically the 
chance of benefit, and where can we source that information? 
User testing of patient information leaflets is helping to make such leaflets fit-for-
purpose, but wordings imposed by regulators are not tested. The wording associated 
with the Black Triangle initiative is a case in point: ‘Warning – this medicine is subject 
to additional monitoring’ means something quite different to some lay people – they 
think it means that they will have more tests or checks (monitoring) if they take the 
medicine. Equally the wordings recommended by PRAC appear less than ideal, and 
are un-tested. 
Finally, Risk Management Plan summaries are designed to inform lay people about 
how the plans for safe use of medicines have been developed and put into practice. 
But what does user testing of RMP Summaries show? Are they fit for purpose? 
This presentation will draw on academic research from the University of Leeds on 
describing benefit and harm information for patients, along with practical examples 
from user testing in practice by Luto Research, a spin out company of the University. 
 
 
 
